Lipella is a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Additionally, Lipella maintains a therapeutic focus on diseases with significant, unaddressed morbidity and mortality where no approved drug therapy currently exists. Lipella completed its initial public offering in December 2022. For more information, please visit www.lipella.com or LinkedIn.
Company profile
Ticker
LIPO
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
LIPELLA PHARMACEUTICALS INC
SEC CIK
LIPO stock data
Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
19 Apr 24
8-K
Amendments to Articles of Incorporation or Bylaws
12 Apr 24
8-K
Entry into a Material Definitive Agreement
15 Mar 24
S-8
Registration of securities for employees
15 Mar 24
424B3
Prospectus supplement
27 Feb 24
10-K
2023 FY
Annual report
27 Feb 24
EFFECT
Notice of effectiveness
9 Feb 24
CORRESP
Correspondence with SEC
6 Feb 24
UPLOAD
Letter from SEC
6 Feb 24
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.41 mm | 2.41 mm | 2.41 mm | 2.41 mm | 2.41 mm | |
Cash burn (monthly) | 234.60 k | 225.99 k | 452.24 k | 365.02 k | 89.83 k | |
Cash used (since last report) | 1.72 mm | 1.66 mm | 3.32 mm | 2.68 mm | 658.52 k | |
Cash remaining | 690.12 k | 753.21 k | -905.32 k | -265.96 k | 1.75 mm | |
Runway (months of cash) | 2.9 | 3.3 | -2.0 | -0.7 | 19.5 |
Institutional ownership, Q2 2023
0.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 3 |
Opened positions | 0 |
Closed positions | 3 |
Increased positions | 1 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 82.49 mm |
Total shares | 38.55 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 34.52 k | $73.87 mm |
UBS UBS Group AG - Registered Shares | 2.42 k | $5.18 mm |
Tower Research Capital | 1.61 k | $3.44 mm |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Mar 24 | Ryan Pruchnic | Stock Options Common Stock | Grant | Acquire A | No | No | 0.77 | 25,000 | 19.25 k | 25,000 |
15 Mar 24 | Naoki Yoshimura | Stock Options Common Stock | Grant | Acquire A | No | No | 0.77 | 25,000 | 19.25 k | 25,000 |
15 Mar 24 | Michael B Chancellor | Stock Options Common Stock | Grant | Acquire A | No | No | 0.77 | 80,000 | 61.60 k | 80,000 |
15 Mar 24 | Lori Birder | Stock Options Common Stock | Grant | Acquire A | No | No | 0.77 | 25,000 | 19.25 k | 25,000 |
15 Mar 24 | Douglas Johnston | Stock Options Common Stock | Grant | Acquire A | No | No | 0.77 | 50,000 | 38.50 k | 50,000 |
News
Maxim Group Initiates Coverage On Lipella Pharmaceuticals with Buy Rating, Announces Price Target of $2
9 Apr 24
Lipella Pharmaceuticals To Publish Abstract Detailing Preclinical Support For New Product Candidate At ASCO 2024
5 Apr 24
Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
5 Mar 24
12 Health Care Stocks Moving In Tuesday's Intraday Session
5 Mar 24
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
5 Mar 24
Press releases
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
17 Apr 24
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024
5 Apr 24
Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis
3 Apr 24